Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 2/20 | 0.51 |
| ▸ | CA9 | Q16790 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1287326 | 0.85 | ALDH1A1 (0.57) | ALDH1A1MEN1KMT2ACYP19A1NPSR1 | |
| SCHEMBL29048576 | 0.85 | MEN1 (0.72) | ALDH1A1MEN1KMT2ACYP19A1CA12 | |
| SCHEMBL29260186 | 0.85 | MEN1 (0.72) | ALDH1A1MEN1KMT2ACA12CA9 | |
| SCHEMBL23451396 | 0.82 | ALDH1A1 (0.60) | ALDH1A1MEN1KMT2ACA12CA9 | |
| SCHEMBL23451385 | 0.82 | ALDH1A1 (0.60) | ALDH1A1MEN1KMT2ACA12CA9 | |
| SCHEMBL15717313 | 0.81 | ALDH1A1 (0.55) | ALDH1A1MEN1KMT2ACA12CA9 | |
| SCHEMBL21569713 | 0.80 | L3MBTL1 (0.66) | MEN1KMT2AL3MBTL1MAPTCA2 | |
| SCHEMBL30822632 | 0.80 | CA12 (0.63) | ALDH1A1MEN1KMT2ACA12CA9 | |
| SCHEMBL3535994 | 0.80 | CA12 (0.63) | ALDH1A1MEN1KMT2ACA12CA9 | |
| SCHEMBL21569712 | 0.79 | AKR1C3 (0.45) | ALDH1A1MEN1KMT2ACYP19A1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210171456-A1 | NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY | GLUCOX BIOTECH AB (SE) | 2021-06-10 | — | — | US | claimed |
| EP-3790858-A1 | NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY | Glucox Biotech AB (SE) | 2021-03-17 | — | — | EP | claimed |
| WO-2019215291-A1 | NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY | GLUCOX BIOTECH AB (SE) | 2019-11-14 | — | — | WO | claimed |
| US-20250136545-A1 | NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY | GLUCOX BIOTECH AB (SE) | 2025-05-01 | — | — | US | disclosed |
| US-12202790-B2 | Sulfonamide derivatives having selective Nox inhibiting activity | GLUCOX BIOTECH AB (SE) | 2025-01-21 | — | — | US | disclosed |
| US-20210171456-A1 | NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY | GLUCOX BIOTECH AB (SE) | 2021-06-10 | — | — | US | disclosed |
| EP-3790858-A1 | NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY | Glucox Biotech AB (SE) | 2021-03-17 | — | — | EP | disclosed |
| WO-2019215291-A1 | NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY | GLUCOX BIOTECH AB (SE) | 2019-11-14 | — | — | WO | disclosed |
| US-7858619-B2 | Substituted tetrahydroisochinolines as MMP inhibitors, related production method and use as medicine | SANOFI-AVENTIS (FR) | 2010-12-28 | — | — | US | disclosed |
| US-20080090821-A1 | SUBSTITUTED TETRAHYDROISOCHINOLINES AS MMP INHIBITORS, RELATED PRODUCTION METHOD AND USE AS MEDICINE | SANOFI-AVENTIS (FR) | 2008-04-17 | — | — | US | disclosed |
| EP-1869001-A1 | SUBSTITUTED TETRAHYDROISOCHINOLINES AS MMP INHIBITORS, RELATED PRODUCTION METHOD AND USE AS MEDICINE | Sanofi-Aventis (FR) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006102998-A1 | SUBSTITUTED TETRAHYDROISOCHINOLINES AS MMP INHIBITORS, RELATED PRODUCTION METHOD AND USE AS MEDICINE | SANOFI-AVENTIS (DE) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12202790-B2 | Sulfonamide derivatives having selective Nox inhibiting activity | NOX4, NOX1, NOX5 | ALDH1A1 493/4885MEN1 4815/4885KMT2A 2602/4885 |
| US-20210171456-A1 | NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY | NOX4, NOX1, NOX5 | ALDH1A1 473/4885MEN1 4816/4885KMT2A 2721/4885 |
| US-20250136545-A1 | NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY | NOX4, NOX1, NOX5 | ALDH1A1 473/4885MEN1 4816/4885KMT2A 2721/4885 |
| US-20080090821-A1 | SUBSTITUTED TETRAHYDROISOCHINOLINES AS MMP INHIBITORS, RELATED PRODUCTION METHOD AND USE AS MEDICINE | MMP9, MMP3, MMP2 | ALDH1A1 304/4885MEN1 1149/4885KMT2A 1806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.